Last week we looked at a broad review of cannabis and cancer research — eight cancer types, five mechanisms, a body of evidence that is serious enough to warrant attention but not yet mature enough to produce clinical recommendations. One of the mechanisms that appeared repeatedly was the inhibition of a signalling pathway called PI3K/AKT/mTOR — a growth and survival axis that is overactivated in many cancers and particularly problematic in ovarian cancer.

This week a new study lands that goes directly at that mechanism. Published in Frontiers in Pharmacology in December 2025, authored by researchers at Khon Kaen University in Thailand, the paper takes two ovarian cancer cell lines — one sensitive to standard chemotherapy, one innately resistant to it — and systematically tests what cannabidiol, THC, and their combination do to each one. The results are specific, mechanistically detailed, and in several respects surprising.

Why Ovarian Cancer Is Such a Difficult Target

Ovarian cancer carries the highest rates of morbidity and mortality among all gynaecological cancers, largely because it is diagnosed late. By the time symptoms become specific enough to identify, the disease has typically progressed to an advanced stage. Over 295,000 patients were diagnosed with ovarian cancer globally in recent data, and approximately 185,000 women died from it — numbers that reflect how consistently this cancer outmanoeuvres early detection.

Standard treatment is surgery followed by platinum-based chemotherapy — cisplatin or carboplatin, which work by cross-linking DNA and triggering apoptosis in cancer cells. The problem is that ovarian cancer frequently develops resistance to these drugs. Once resistance is established, treatment options narrow dramatically and patient outcomes deteriorate. This is the clinical context that makes the search for alternative or adjunctive agents genuinely urgent, not merely academically interesting.

The PI3K/AKT/mTOR pathway sits at the centre of why ovarian cancer is so hard to treat. It is overactivated in a significant proportion of ovarian cancers, and it drives cell proliferation, survival, and chemoresistance. PTEN — phosphatase and tensin homolog — is the natural brake on this pathway. In many ovarian cancers, PTEN is lost or silenced, removing that brake and allowing the pathway to run unchecked. Restoring PTEN function is therefore a legitimate therapeutic goal, and it is one the cannabinoid combination in this study appears to address.

How the Study Was Designed

The researchers worked with three cell lines. A2780 is a platinum-sensitive ovarian cancer model. SKOV3 is a platinum-resistant ovarian cancer model. IOSE80 is a non-tumorigenic ovarian epithelial cell line used to assess whether the treatments harm healthy cells. Including the non-cancer cell line is critical — it allows the researchers to measure selectivity, which is the difference between a therapeutic agent and a poison.

Compounds were tested individually at multiple concentrations across 24, 48, and 72 hours. They were also tested in combination at three ratios — 1:1, 1:2, and 1:4 CBD to THC — to assess how the interaction between the two compounds changes depending on their proportions. The Chou-Talalay method was used to calculate combination index values and determine whether the interaction between CBD and THC is synergistic, additive, or antagonistic at each ratio and effect level. This is the gold standard mathematical framework for combination drug analysis, and its inclusion gives the findings considerably more rigor than a simple cell viability comparison would provide.

The Selectivity Finding — Cancer Cells vs Healthy Cells

The first and perhaps most clinically important finding is one we touched on in last week's broader review: cannabinoids appear to be more toxic to cancer cells than to healthy ones, and by a meaningful margin.

IC50 is the concentration required to kill 50% of cells. A lower IC50 means a compound is more potent against that cell type. The cancer cell lines required four to six times less CBD or THC to achieve 50% cell death than the healthy IOSE80 cells did. This selectivity window is not enormous, but it is consistent and statistically significant, and it aligns with what the broader literature has been finding across multiple cancer types, as we documented last week.

The Synergy Question — When Does Combining CBD and THC Help?

The combination index analysis is where this study gets genuinely interesting — and where it delivers a warning as much as a finding.

In A2780 cells at the 1:1 ratio — equal parts CBD and THC — the combination index values were 0.7, 0.5, and 0.5 at 20%, 50%, and 80% cell death respectively. A combination index below 1 indicates synergy. These numbers mean that CBD and THC at equal proportions work better together against A2780 cells than either would at equivalent doses alone, and the synergy becomes more pronounced as the desired level of cell killing increases.

In SKOV3 cells — the platinum-resistant line — the picture is more complex. At the 1:1 ratio, the combination was antagonistic at lower cell killing levels but synergistic at higher ones. This concentration-dependent switch from antagonism to synergy is not a failure of the approach; it is a signal that the interaction between CBD and THC involves multiple molecular mechanisms that engage at different thresholds. At lower concentrations, the two compounds may compete for overlapping receptor sites. At higher concentrations, their complementary pathways — mitochondrial stress, ROS generation, and PI3K/AKT/mTOR inhibition — appear to reinforce each other.

In IOSE80 healthy cells, all combination ratios showed additive to antagonistic effects — meaning the combination does not achieve synergistic toxicity against non-cancerous tissue. This is the safety finding the researchers were looking for, and it held consistently across all tested ratios and effect levels.

What the Combination Actually Does to Cancer Cells

Beyond the cytotoxicity measurements, the researchers investigated what is actually happening inside the cells when the combination is applied. The findings span four distinct biological effects.

The researchers also assessed migration and invasion — two behaviours that are prerequisites for metastasis. Using Transwell assays with Matrigel, they found that CBD and THC individually reduced both migration and invasion in A2780 and SKOV3 cells, and the combination suppressed both behaviours more strongly than either compound alone. This anti-metastatic finding adds a dimension beyond direct cell killing: even if some cancer cells survive the treatment, their capacity to spread may be significantly impaired.

The Molecular Mechanism — PI3K, AKT, mTOR, and PTEN

This is the section of the study that connects most directly to last week's broader review. We noted then that the PI3K/AKT/mTOR signalling axis is frequently overactivated in ovarian cancer and that cannabidiol had shown consistent ability to inhibit this pathway in cholangiocarcinoma and other cancer types. This study provides the most detailed picture yet of how that inhibition operates in ovarian cancer specifically.

Western blot analysis — a technique for measuring protein levels and activity — revealed the following after treatment with CBD, THC, and their combination at 2.5:2.5 micromolar:

The significance of the PTEN finding warrants a moment of explanation. PTEN normally works by removing a phosphate group from a molecule called PIP3, converting it to PIP2. This conversion blocks the signal that activates AKT. When PTEN is phosphorylated at specific sites on its C-terminus — serine 380, threonine 382, and threonine 383 — it folds into a closed configuration that is more stable but less catalytically active. It is still present in the cell, but it is not doing its job.

What the combination treatment appears to do is increase the total amount of PTEN protein while simultaneously reducing its phosphorylation — shifting more PTEN into the open, active configuration. The result is a tumour suppressor that is not only more abundant but also more functional. Combined with the direct reduction in PI3K, AKT, and mTOR phosphorylation, this represents a two-pronged attack on the oncogenic pathway: switching off the accelerator while reactivating the brake.

Connecting This to What We Already Knew

Last week's review of the broader cancer literature documented five mechanisms through which cannabinoids appear to attack cancer cells: apoptosis induction, autophagy induction, tumour regression, inhibition of proliferation, and suppression of invasion and angiogenesis. This study confirms four of those five in a single, tightly controlled experiment on a specific cancer type, and it adds mechanistic depth to each of them.

It also extends last week's observation about cannabidiol as an adjunct that amplifies existing treatments. We noted, in the context of liver cancer, that CBD enhanced the anticancer activity of cabozantinib. In the context of ovarian cancer, the same principle applies — but here the combination is cannabinoid-to-cannabinoid rather than cannabinoid-to-chemotherapy. CBD and THC appear to engage complementary molecular pathways that, at the right ratio and concentration, produce effects neither achieves alone.

The researchers themselves draw an explicit parallel to previous work showing that CBD and THC combinations can achieve synergistic or additive anti-cancer effects in other cancer models, including glioma, where the combination with temozolomide produced the most promising clinical trial results in the broader cannabis-cancer literature — the 83% one-year survival rate in glioblastoma patients we highlighted last week.

What This Study Cannot Tell Us

This is rigorous in vitro science, and the authors are honest about its limits. The cells tested in a laboratory dish do not capture the complexity of a living tumour — its vasculature, its immune microenvironment, the variation in oxygenation and nutrient availability across different regions, and the pharmacokinetic reality of how cannabinoids are absorbed, distributed, metabolised, and eliminated in a living body.

The study also did not include a full ADMET assessment — the analysis of absorption, distribution, metabolism, excretion, and toxicity that would be required before a clinical application could be seriously planned. The authors acknowledge this gap and call for in silico and in vitro pharmacokinetic modelling as next steps. And critically, no in vivo work was conducted in this study. The molecular findings need validation in animal models before the translation to clinical relevance can be claimed.

The ratio dependence of the synergy is also a practical constraint that will not be simple to address. The difference between the 1:1 ratio — which produced synergy in A2780 cells — and the 1:4 ratio — which produced strong antagonism in both cancer lines — is not a minor dosing question. It is a fundamental design problem for any therapeutic formulation. Getting this wrong would not merely reduce efficacy; it would actively undermine it.

What It Means for How We Think About the Plant

Something emerges from looking at this study alongside last week's broader review: the cannabis plant may contain a therapeutic system that is greater than any of its individual parts. CBD alone inhibits the PI3K/AKT/mTOR pathway. THC alone does so less consistently. Together, at the right ratio, they inhibit the pathway more powerfully than either does alone and simultaneously restore PTEN function — a combination of effects that neither achieves independently.

This is a more sophisticated version of what the cannabis research community has long described as the entourage effect — the idea that compounds in the plant work together in ways that individual molecules cannot replicate alone. What this study adds is a mechanistic explanation for at least one instance of that interaction, at a level of biological detail that moves the concept from intuition into evidence.

For growers and producers, the implication is one we have raised before in this series: the chemical profile of a cannabis variety matters, and not just for the reasons the commercial market currently emphasises. The ratio of CBD to THC in a cultivar is not merely a regulatory or psychoactivity consideration. It is, according to this research, a variable that determines whether two compounds in the plant will work synergistically or antagonistically against cancer cells. That is a more consequential version of the CBD-to-THC ratio conversation than the industry is currently having.